COMBINED THERAPY WITH ARBEKACIN AND FOSFOMYCIN FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS
We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination ofarbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy....
Gespeichert in:
| Veröffentlicht in: | Japanese journal of antibiotics 1994/06/25, Vol.47(6), pp.798-803 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 803 |
|---|---|
| container_issue | 6 |
| container_start_page | 798 |
| container_title | Japanese journal of antibiotics |
| container_volume | 47 |
| creator | KONO, KENJI TAKEDA, SEIJI TATARA, ICHIRO ARAKAWA, KIKUO TANAKA, HIROAKI MIYAKE, SHUNJI MINAMIKAWA, HIROMICHI HOSHINO, HIROSUKE SATO, MIKIO HATTORI, FUMITADA KAWAHIRA, KOZABURO |
| description | We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination ofarbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy. This combination thus appeared to be an effective regimen for the treatment of MRSA infections. However, its bacteriological efficacy against concomitant Pseudomonas aeruginosa strains was only 16.7% (1/6). In addition, in 4 episodes of superinfection involving P. aeruginosa strains developed during the combination therapy. |
| doi_str_mv | 10.11553/antibiotics1968b.47.798 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_76675219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76675219</sourcerecordid><originalsourceid>FETCH-LOGICAL-j254t-b75104c7da2028c9d7b5fa9281116f294c8b7e9379d6b1ec034dfde725cb3d73</originalsourceid><addsrcrecordid>eNpdkc1ugzAQhK2qVRqleYRKPvVGim3A9pE4UNwSiICoygkZcFqi_BXIoW9fokQ5dA8zWs2nPcwCAJE5Qci2yavad3VRH7q6bBF3WDGx6IRydgeGGDHHsC1K78HQJA4zMGXoEYzbdmP2w5hlEjIAA2bSHuVDUIt4PpWRN4NZ4CXuYgU_ZRZAN5l6H66QEXSjGfTj1I_nq_Pqxwmce1kghQxDGRmJl8o0c6MM9roIVmEsYiGWKXSXidebjHxPZDKO0ifwsFbbVo-vPgKZ72UiMML4TQo3NDbYtjqjoDYyrZJWCpuYlbyihb1WHDOEkLPG3CpZQTUnlFdOgXRpEqtaV5piuyxIRckIvFzOHpvDz0m3Xb6r21Jvt2qvD6c2p45DbYx4Dz5fwVOx01V-bOqdan7zazV9_n7JN22nvvQtV03f-1bn_5-QWzR3ztJ_4gaV36rJ9Z78AYdmfPY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76675219</pqid></control><display><type>article</type><title>COMBINED THERAPY WITH ARBEKACIN AND FOSFOMYCIN FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>KONO, KENJI ; TAKEDA, SEIJI ; TATARA, ICHIRO ; ARAKAWA, KIKUO ; TANAKA, HIROAKI ; MIYAKE, SHUNJI ; MINAMIKAWA, HIROMICHI ; HOSHINO, HIROSUKE ; SATO, MIKIO ; HATTORI, FUMITADA ; KAWAHIRA, KOZABURO</creator><creatorcontrib>KONO, KENJI ; TAKEDA, SEIJI ; TATARA, ICHIRO ; ARAKAWA, KIKUO ; TANAKA, HIROAKI ; MIYAKE, SHUNJI ; MINAMIKAWA, HIROMICHI ; HOSHINO, HIROSUKE ; SATO, MIKIO ; HATTORI, FUMITADA ; KAWAHIRA, KOZABURO</creatorcontrib><description>We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination ofarbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy. This combination thus appeared to be an effective regimen for the treatment of MRSA infections. However, its bacteriological efficacy against concomitant Pseudomonas aeruginosa strains was only 16.7% (1/6). In addition, in 4 episodes of superinfection involving P. aeruginosa strains developed during the combination therapy.</description><identifier>ISSN: 0368-2781</identifier><identifier>EISSN: 2186-5477</identifier><identifier>DOI: 10.11553/antibiotics1968b.47.798</identifier><identifier>PMID: 8072189</identifier><language>eng</language><publisher>Japan: Japan Antibiotics Research Association</publisher><subject>Aminoglycosides ; Anti-Bacterial Agents ; Dibekacin - analogs & derivatives ; Dibekacin - therapeutic use ; Drug Therapy, Combination - therapeutic use ; Fosfomycin - pharmacology ; Fosfomycin - therapeutic use ; Humans ; Methicillin Resistance ; Microbial Sensitivity Tests ; Pseudomonas aeruginosa - drug effects ; Pseudomonas Infections - complications ; Pseudomonas Infections - drug therapy ; Staphylococcal Infections - complications ; Staphylococcal Infections - drug therapy ; Staphylococcus aureus - drug effects ; Superinfection - drug therapy</subject><ispartof>The Japanese Journal of Antibiotics, 1994/06/25, Vol.47(6), pp.798-803</ispartof><rights>Japan Antibiotics Research Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8072189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KONO, KENJI</creatorcontrib><creatorcontrib>TAKEDA, SEIJI</creatorcontrib><creatorcontrib>TATARA, ICHIRO</creatorcontrib><creatorcontrib>ARAKAWA, KIKUO</creatorcontrib><creatorcontrib>TANAKA, HIROAKI</creatorcontrib><creatorcontrib>MIYAKE, SHUNJI</creatorcontrib><creatorcontrib>MINAMIKAWA, HIROMICHI</creatorcontrib><creatorcontrib>HOSHINO, HIROSUKE</creatorcontrib><creatorcontrib>SATO, MIKIO</creatorcontrib><creatorcontrib>HATTORI, FUMITADA</creatorcontrib><creatorcontrib>KAWAHIRA, KOZABURO</creatorcontrib><title>COMBINED THERAPY WITH ARBEKACIN AND FOSFOMYCIN FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS</title><title>Japanese journal of antibiotics</title><addtitle>Jpn. J. Antibiotics</addtitle><description>We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination ofarbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy. This combination thus appeared to be an effective regimen for the treatment of MRSA infections. However, its bacteriological efficacy against concomitant Pseudomonas aeruginosa strains was only 16.7% (1/6). In addition, in 4 episodes of superinfection involving P. aeruginosa strains developed during the combination therapy.</description><subject>Aminoglycosides</subject><subject>Anti-Bacterial Agents</subject><subject>Dibekacin - analogs & derivatives</subject><subject>Dibekacin - therapeutic use</subject><subject>Drug Therapy, Combination - therapeutic use</subject><subject>Fosfomycin - pharmacology</subject><subject>Fosfomycin - therapeutic use</subject><subject>Humans</subject><subject>Methicillin Resistance</subject><subject>Microbial Sensitivity Tests</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas Infections - complications</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Staphylococcal Infections - complications</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Superinfection - drug therapy</subject><issn>0368-2781</issn><issn>2186-5477</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1ugzAQhK2qVRqleYRKPvVGim3A9pE4UNwSiICoygkZcFqi_BXIoW9fokQ5dA8zWs2nPcwCAJE5Qci2yavad3VRH7q6bBF3WDGx6IRydgeGGDHHsC1K78HQJA4zMGXoEYzbdmP2w5hlEjIAA2bSHuVDUIt4PpWRN4NZ4CXuYgU_ZRZAN5l6H66QEXSjGfTj1I_nq_Pqxwmce1kghQxDGRmJl8o0c6MM9roIVmEsYiGWKXSXidebjHxPZDKO0ifwsFbbVo-vPgKZ72UiMML4TQo3NDbYtjqjoDYyrZJWCpuYlbyihb1WHDOEkLPG3CpZQTUnlFdOgXRpEqtaV5piuyxIRckIvFzOHpvDz0m3Xb6r21Jvt2qvD6c2p45DbYx4Dz5fwVOx01V-bOqdan7zazV9_n7JN22nvvQtV03f-1bn_5-QWzR3ztJ_4gaV36rJ9Z78AYdmfPY</recordid><startdate>199406</startdate><enddate>199406</enddate><creator>KONO, KENJI</creator><creator>TAKEDA, SEIJI</creator><creator>TATARA, ICHIRO</creator><creator>ARAKAWA, KIKUO</creator><creator>TANAKA, HIROAKI</creator><creator>MIYAKE, SHUNJI</creator><creator>MINAMIKAWA, HIROMICHI</creator><creator>HOSHINO, HIROSUKE</creator><creator>SATO, MIKIO</creator><creator>HATTORI, FUMITADA</creator><creator>KAWAHIRA, KOZABURO</creator><general>Japan Antibiotics Research Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>199406</creationdate><title>COMBINED THERAPY WITH ARBEKACIN AND FOSFOMYCIN FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS</title><author>KONO, KENJI ; TAKEDA, SEIJI ; TATARA, ICHIRO ; ARAKAWA, KIKUO ; TANAKA, HIROAKI ; MIYAKE, SHUNJI ; MINAMIKAWA, HIROMICHI ; HOSHINO, HIROSUKE ; SATO, MIKIO ; HATTORI, FUMITADA ; KAWAHIRA, KOZABURO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j254t-b75104c7da2028c9d7b5fa9281116f294c8b7e9379d6b1ec034dfde725cb3d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Aminoglycosides</topic><topic>Anti-Bacterial Agents</topic><topic>Dibekacin - analogs & derivatives</topic><topic>Dibekacin - therapeutic use</topic><topic>Drug Therapy, Combination - therapeutic use</topic><topic>Fosfomycin - pharmacology</topic><topic>Fosfomycin - therapeutic use</topic><topic>Humans</topic><topic>Methicillin Resistance</topic><topic>Microbial Sensitivity Tests</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas Infections - complications</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Staphylococcal Infections - complications</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Superinfection - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KONO, KENJI</creatorcontrib><creatorcontrib>TAKEDA, SEIJI</creatorcontrib><creatorcontrib>TATARA, ICHIRO</creatorcontrib><creatorcontrib>ARAKAWA, KIKUO</creatorcontrib><creatorcontrib>TANAKA, HIROAKI</creatorcontrib><creatorcontrib>MIYAKE, SHUNJI</creatorcontrib><creatorcontrib>MINAMIKAWA, HIROMICHI</creatorcontrib><creatorcontrib>HOSHINO, HIROSUKE</creatorcontrib><creatorcontrib>SATO, MIKIO</creatorcontrib><creatorcontrib>HATTORI, FUMITADA</creatorcontrib><creatorcontrib>KAWAHIRA, KOZABURO</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of antibiotics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KONO, KENJI</au><au>TAKEDA, SEIJI</au><au>TATARA, ICHIRO</au><au>ARAKAWA, KIKUO</au><au>TANAKA, HIROAKI</au><au>MIYAKE, SHUNJI</au><au>MINAMIKAWA, HIROMICHI</au><au>HOSHINO, HIROSUKE</au><au>SATO, MIKIO</au><au>HATTORI, FUMITADA</au><au>KAWAHIRA, KOZABURO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COMBINED THERAPY WITH ARBEKACIN AND FOSFOMYCIN FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS</atitle><jtitle>Japanese journal of antibiotics</jtitle><addtitle>Jpn. J. Antibiotics</addtitle><date>1994-06</date><risdate>1994</risdate><volume>47</volume><issue>6</issue><spage>798</spage><epage>803</epage><pages>798-803</pages><issn>0368-2781</issn><eissn>2186-5477</eissn><abstract>We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination ofarbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy. This combination thus appeared to be an effective regimen for the treatment of MRSA infections. However, its bacteriological efficacy against concomitant Pseudomonas aeruginosa strains was only 16.7% (1/6). In addition, in 4 episodes of superinfection involving P. aeruginosa strains developed during the combination therapy.</abstract><cop>Japan</cop><pub>Japan Antibiotics Research Association</pub><pmid>8072189</pmid><doi>10.11553/antibiotics1968b.47.798</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0368-2781 |
| ispartof | The Japanese Journal of Antibiotics, 1994/06/25, Vol.47(6), pp.798-803 |
| issn | 0368-2781 2186-5477 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76675219 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aminoglycosides Anti-Bacterial Agents Dibekacin - analogs & derivatives Dibekacin - therapeutic use Drug Therapy, Combination - therapeutic use Fosfomycin - pharmacology Fosfomycin - therapeutic use Humans Methicillin Resistance Microbial Sensitivity Tests Pseudomonas aeruginosa - drug effects Pseudomonas Infections - complications Pseudomonas Infections - drug therapy Staphylococcal Infections - complications Staphylococcal Infections - drug therapy Staphylococcus aureus - drug effects Superinfection - drug therapy |
| title | COMBINED THERAPY WITH ARBEKACIN AND FOSFOMYCIN FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T09%3A27%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COMBINED%20THERAPY%20WITH%20ARBEKACIN%20AND%20FOSFOMYCIN%20FOR%20METHICILLIN-RESISTANT%20STAPHYLOCOCCUS%20AUREUS%20INFECTIONS&rft.jtitle=Japanese%20journal%20of%20antibiotics&rft.au=KONO,%20KENJI&rft.date=1994-06&rft.volume=47&rft.issue=6&rft.spage=798&rft.epage=803&rft.pages=798-803&rft.issn=0368-2781&rft.eissn=2186-5477&rft_id=info:doi/10.11553/antibiotics1968b.47.798&rft_dat=%3Cproquest_pubme%3E76675219%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76675219&rft_id=info:pmid/8072189&rfr_iscdi=true |